Acumen Pharmaceuticals Inc
NASDAQ:ABOS
Acumen Pharmaceuticals Inc
NASDAQ:ABOS
Price:
3.3397 USD
2.76%
Market Closed
Updated:
May 2, 2024
Acumen Pharmaceuticals Inc
Cash from Financing Activities
|
Acumen Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Acumen Pharmaceuticals Inc
NASDAQ:ABOS
|
Cash from Financing Activities
$151.8m
|
CAGR 3-Years
50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Acumen Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
151.8m
USD
151.8m
USD
Based on the financial report for Dec 31, 2023, Acumen Pharmaceuticals Inc's Cash from Financing Activities amounts to 151.8m USD.
What is Acumen Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
50%
50%
Over the last year, the Cash from Financing Activities growth was 3 781%. The average annual Cash from Financing Activities growth rates for Acumen Pharmaceuticals Inc have been 50% over the past three years .
You don't have any saved screeners yet
